Lumira Ventures

Puzzle Medical Devices Inc. is a Montreal-based company founded in 2018 that specializes in developing advanced heart pump devices for the treatment of heart failure. The company's flagship product, the ModulHeart, features a modular design that allows for percutaneous implantation, providing hemodynamic support through multiple pumps anchored in parallel in the descending aorta. This innovative approach aims to reduce cardiac afterload and enhance renal perfusion for patients with advanced heart failure who are not candidates for heart transplants or surgical mechanical circulatory support. The ModulHeart is designed to improve patient mobility, minimize risks of complications such as bleeding and stroke, and enhance overall quality of life by offering sustained symptom relief and reducing re-hospitalizations. Puzzle Medical has made significant progress, having completed its first-in-human study in 2022, which showed improvements in cardiac and kidney function in all participants, and received FDA Breakthrough Device Designation in 2021.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Sound Blade Medical is an early-stage medical device company that specializes in developing innovative, non-invasive therapies using endoscopic histotripsy. This technology employs focused ultrasound, guided by real-time imaging, to precisely destroy targeted tissue without heat, ionizing radiation, or surgical invasion. The company aims to revolutionize healthcare by enhancing endoscopic procedures, offering a more precise and safer alternative to traditional treatments.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

KisoJi Biotechnology is an early-stage biotechnology company focused on the development of innovative antibodies for cancer treatment and other therapeutic indications. The company employs a unique approach that allows for the comprehensive identification and visualization of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's antibody platform features multi-species single-domain antibody transgenic mice and utilizes AI-driven antibody fingerprinting to match specific epitopes on various targets. This technology enables the creation of robust, easily manufacturable multi-specific antibodies, aimed at significantly improving treatment outcomes for cancer patients. Through its advanced methodologies, KisoJi is positioned to enhance the efficacy of cancer therapies and contribute to the broader field of oncology.

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting the KCC2, a key mediator of inhibition in the brain. The company leverages groundbreaking research from institutions such as Boston Children’s Hospital, Harvard, and Laval University to create a proprietary neuron-specific K-Cl cotransporter discovery engine. This innovative platform aims to enhance the treatment of various conditions, including epilepsy, pain, and other central nervous system pathologies, by fine-tuning neuronal inhibition. Through its efforts, Axonis Therapeutics seeks to contribute to the healthcare industry's ability to combat neurodegeneration, restore neuronal excitation, and promote neuron regeneration, ultimately improving the quality of life for individuals affected by these disorders.

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

SpectraWAVE, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in the development and manufacturing of optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Its flagship product includes a spectroscopy catheter that assists in diagnosing and treating cardiovascular conditions. SpectraWAVE has also developed an advanced intravascular imaging technology that integrates proven imaging methodologies to improve outcomes for coronary artery disease. This technology provides interventional cardiologists with critical optical and computational insights to optimize stent interventions and identify patients and plaques at risk of adverse coronary events, ultimately aiming to improve patient treatment and outcomes in the field of cardiovascular health.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Endogenex is a medical technology company founded in 2017, focused on developing innovative solutions for patients with type 2 diabetes. The company has created an endoscopic procedure that employs pulsed electric fields to regenerate the duodenal mucosa, aiming to enhance glycemic control in individuals suffering from this condition. By providing a novel therapy, Endogenex seeks to empower patients to better manage their blood glucose levels and improve their overall health outcomes.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

Cyrano Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for individuals suffering from taste and smell disorders. Founded in 2014 and based in Washington, D.C., the company is working on an intranasal product, CYR-001, which repurposes an existing approved molecule, Theophylline, to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, CYR-001 demonstrated promising results, with eight out of ten participants showing significant improvements within two weeks and no reported side effects. The company's approach includes a diagnostic kit designed to assess and quantify the severity of sensory loss, thereby aiding caregivers in enhancing the quality of life for affected patients, including those undergoing chemotherapy who often experience changes in their sensory perception.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Specific Biologics is a biotechnology company focused on developing innovative gene-editing technologies for treating genetic diseases at their source within the body. The company's core technology involves a dual-cleaving nuclease that can be safely delivered to cells, leveraging the cell's natural DNA repair mechanisms to either enhance repair or create predictable deletions. This approach aims to address various genetic conditions by precisely editing the genome.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

PIC Therapeutics, Inc. is a biotechnology company dedicated to advancing cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and headquartered in Boston, Massachusetts, the company develops precision-based therapeutics that target the master switch of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This innovative approach has the potential to simultaneously address multiple oncogenic drivers, paving the way for a new generation of cancer therapies that could significantly enhance patient outcomes.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company focused on treating and preventing cognitive deficits associated with various brain disorders and aging. The company develops small molecule therapeutics aimed at transforming the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Their goal is to enable patients to potentially reverse impairments and resolve previously unresolvable symptoms.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Congruence Therapeutics is a biotechnology company focused on developing pharmacological stabilizers for treating rare diseases. The company leverages computational and experimental drug discovery methods, along with structural bioinformatics, computational chemistry, and machine learning, to create an in silico platform. This platform enables the design of novel small molecules targeted at diseases caused by protein misfolding.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Specific Biologics is a biotechnology company focused on developing innovative gene-editing technologies for treating genetic diseases at their source within the body. The company's core technology involves a dual-cleaving nuclease that can be safely delivered to cells, leveraging the cell's natural DNA repair mechanisms to either enhance repair or create predictable deletions. This approach aims to address various genetic conditions by precisely editing the genome.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapeutics for Long QT Syndrome and other arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, as well as atrial fibrillation and treatment-resistant cancers. Thryv Therapeutics specializes in creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to provide therapies that can significantly reduce the risk of sudden cardiac death and enhance the quality of life for patients affected by these serious conditions.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, that specializes in restoring protein homeostasis through innovative small molecule therapies. The company develops Protein Homeostatic Modulators, including a small molecular glue that targets cereblon for protein degradation, with applications in oncology, inflammation, and other diseases. BioTheryX employs its proprietary PRODEGY platform, which utilizes a library of cereblon binders to design targeted protein degraders (TPDs). Among its key products is BTX-A51, an oral multi-kinase inhibitor aimed at treating specific leukemic stem cell targets and preventing the transcription of oncogenic genes. Founded in 2007, BioTheryX aims to address unmet medical needs by leveraging its expertise in targeted protein degradation.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Founded in 2018 and headquartered in Toronto, Canada, the company specializes in induced pluripotent stem cell (iPSC) AlloCAR therapy products targeting non-Hodgkin lymphoma, leukemia, and multiple myeloma. Notch Therapeutics has created a proprietary T-cell production platform that allows for precise control of Notch signaling, a critical factor in T-cell development. This innovative approach addresses key limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. The technology empowers healthcare professionals to engineer stem cells tailored to the complex biology of various diseases, thereby enhancing the efficacy of cell therapies.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Cyrano Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for individuals suffering from taste and smell disorders. Founded in 2014 and based in Washington, D.C., the company is working on an intranasal product, CYR-001, which repurposes an existing approved molecule, Theophylline, to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, CYR-001 demonstrated promising results, with eight out of ten participants showing significant improvements within two weeks and no reported side effects. The company's approach includes a diagnostic kit designed to assess and quantify the severity of sensory loss, thereby aiding caregivers in enhancing the quality of life for affected patients, including those undergoing chemotherapy who often experience changes in their sensory perception.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.

IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.

Bright Angel Therapeutics is a biopharmaceutical company focused on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the efficacy of existing antifungal therapies and combat drug resistance by specifically targeting the stress responses that fungi rely on for survival, virulence, and resistance to treatment. By addressing the challenges posed by the frequent emergence of clinical resistance, Bright Angel Therapeutics seeks to reduce the severe morbidity and mortality associated with infections caused by various fungal pathogens.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Bardy Diagnostics, Inc. is a medical technology company focused on developing and manufacturing innovative cardiac monitoring devices. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight and discreet cardiac patch that can be worn comfortably for up to seven days, even during exercise or showering. The CAM is specifically designed with a narrow, hourglass shape to enhance comfort, particularly for women. This device captures low amplitude and frequency electrical signals that form the P-wave, allowing for accurate arrhythmia detection and improving clinical decision-making. Bardy Diagnostics also offers BDxCONNECT, a patient management system that facilitates the creation, access, and management of patient CAM reports. Founded in 2013 and headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey, Bardy Diagnostics aims to enhance clinical management and outcomes through advanced ECG detection technologies that promote greater patient compliance and more confident diagnoses by physicians.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Exact Imaging is a Canadian company based in Markham that specializes in developing high-resolution micro-ultrasound systems for urological applications, particularly in the diagnosis and treatment of prostate cancer. The flagship ExactVu system operates at 29 MHz, providing exceptional imaging resolution that allows for the visualization and targeting of suspicious regions within the prostate. This technology facilitates both targeted and systematic TRUS biopsies, enhancing the accuracy of prostate cancer diagnostics. Additionally, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI data to further improve imaging and biopsy guidance. Founded in 2003 and originally named Imagistx, Inc., the company rebranded to Exact Imaging in March 2015.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.

Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company operating in Canada and the United States, dedicated to developing and commercializing treatments for rare and auto-immune diseases. The company's primary products include Rasuvo and Metoject, which are formulations of methotrexate for rheumatoid arthritis and other auto-immune conditions. Additionally, Medexus offers IXINITY, a therapeutic for Hemophilia B, and Rupall, indicated for various allergic conditions. The company's portfolio also features Cuvposa for sialorrhea, Gliolan for brain tumor visualization, and Treosulfan, used in stem cell transplantation preparation. Medexus Pharmaceuticals, based in Verdun, Canada, previously operated as Pediapharm Inc. and has since expanded its focus to include a range of therapeutic areas such as rheumatology, oncology, hematology, allergy, and pediatrics.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Endotronix Inc. is a medical technology company based in Lisle, Illinois, founded in 2007. It specializes in the development of advanced hemodynamic monitoring solutions aimed at improving the management of heart failure. The company’s flagship product is a miniaturized, wireless implantable pressure sensor that is designed to be used during interventional cardiovascular procedures. This sensor interfaces with an external measurement device and is part of a broader platform that includes a cloud-based disease management system. Through its innovative technology, Endotronix enables healthcare professionals to detect worsening heart failure earlier, facilitating proactive patient management and enhancing clinical outcomes. The company's approach connects patients, clinicians, and reimbursement teams, providing a comprehensive solution for outpatient hemodynamic management.

KisoJi Biotechnology is an early-stage biotechnology company focused on the development of innovative antibodies for cancer treatment and other therapeutic indications. The company employs a unique approach that allows for the comprehensive identification and visualization of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's antibody platform features multi-species single-domain antibody transgenic mice and utilizes AI-driven antibody fingerprinting to match specific epitopes on various targets. This technology enables the creation of robust, easily manufacturable multi-specific antibodies, aimed at significantly improving treatment outcomes for cancer patients. Through its advanced methodologies, KisoJi is positioned to enhance the efficacy of cancer therapies and contribute to the broader field of oncology.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

KalGene Pharmaceuticals Inc. is a private biotechnology company based in Candiac, Canada, focused on developing precision medicine for the treatment of Alzheimer’s disease. Established in 2006, KalGene collaborates with leading clinician-scientists and academic institutions across North America and Europe. The company specializes in creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates. Through personalized medicine, KalGene seeks to predict patient responses to specific therapies before treatment begins, enabling physicians to tailor interventions based on individual biological signatures and needs.

Exact Imaging is a Canadian company based in Markham that specializes in developing high-resolution micro-ultrasound systems for urological applications, particularly in the diagnosis and treatment of prostate cancer. The flagship ExactVu system operates at 29 MHz, providing exceptional imaging resolution that allows for the visualization and targeting of suspicious regions within the prostate. This technology facilitates both targeted and systematic TRUS biopsies, enhancing the accuracy of prostate cancer diagnostics. Additionally, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI data to further improve imaging and biopsy guidance. Founded in 2003 and originally named Imagistx, Inc., the company rebranded to Exact Imaging in March 2015.

KisoJi Biotechnology is an early-stage biotechnology company focused on the development of innovative antibodies for cancer treatment and other therapeutic indications. The company employs a unique approach that allows for the comprehensive identification and visualization of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's antibody platform features multi-species single-domain antibody transgenic mice and utilizes AI-driven antibody fingerprinting to match specific epitopes on various targets. This technology enables the creation of robust, easily manufacturable multi-specific antibodies, aimed at significantly improving treatment outcomes for cancer patients. Through its advanced methodologies, KisoJi is positioned to enhance the efficacy of cancer therapies and contribute to the broader field of oncology.

Exact Imaging is a Canadian company based in Markham that specializes in developing high-resolution micro-ultrasound systems for urological applications, particularly in the diagnosis and treatment of prostate cancer. The flagship ExactVu system operates at 29 MHz, providing exceptional imaging resolution that allows for the visualization and targeting of suspicious regions within the prostate. This technology facilitates both targeted and systematic TRUS biopsies, enhancing the accuracy of prostate cancer diagnostics. Additionally, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI data to further improve imaging and biopsy guidance. Founded in 2003 and originally named Imagistx, Inc., the company rebranded to Exact Imaging in March 2015.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

KalGene Pharmaceuticals Inc. is a private biotechnology company based in Candiac, Canada, focused on developing precision medicine for the treatment of Alzheimer’s disease. Established in 2006, KalGene collaborates with leading clinician-scientists and academic institutions across North America and Europe. The company specializes in creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates. Through personalized medicine, KalGene seeks to predict patient responses to specific therapies before treatment begins, enabling physicians to tailor interventions based on individual biological signatures and needs.

Engage Therapeutics, Inc. is a biopharmaceutical company based in Summit, New Jersey, focused on developing innovative therapies for individuals experiencing uncontrolled epileptic seizures. Its lead investigational product, Staccato alprazolam, is a small, handheld drug-device combination designed for the rapid cessation of active and acute seizures. Utilizing an FDA-approved delivery system, the Staccato device administers alprazolam, an established benzodiazepine, in a single inhalation. The product has shown promise in a Phase 2a proof of concept study, which indicated potential reductions in seizures within a photosensitivity model. Engage Therapeutics is advancing Staccato alprazolam through clinical development, employing a 505(b)(2) regulatory pathway to facilitate its market entry.

Stellar Biotechnologies, Inc. is a biotechnology company that specializes in the sustainable manufacture of keyhole limpet hemocyanin (KLH), an immune-stimulating protein. KLH is utilized as a carrier molecule in therapeutic vaccine development targeting various conditions, including cancers, immune disorders, Alzheimer's disease, and inflammatory diseases. The company offers KLH in multiple grades and formulations for drug development and research applications, as well as in vitro diagnostic kits for research and preclinical use. Stellar's clientele includes biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Based in Port Hueneme, California, Stellar Biotechnologies is recognized for its contributions to advancing immunotherapies and assessing immune system function through its innovative products.

Edesa Biotech is a clinical-stage biotechnology company dedicated to developing innovative treatments for dermatological and anorectal diseases, with a primary focus on inflammatory and immune-related conditions. The company aims to create safe and effective alternatives to topical steroids, which can have undesirable side effects. Its lead product candidate, EB01, is a non-steroidal anti-inflammatory treatment specifically designed for chronic allergic contact dermatitis and has shown statistically significant improvements in clinical studies. Additionally, Edesa Biotech is developing EB05, a monoclonal antibody therapy targeting hospitalized COVID-19 patients. The company is engaged in research and development, manufacturing, and the commercialization of its pharmaceutical products.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Exact Imaging is a Canadian company based in Markham that specializes in developing high-resolution micro-ultrasound systems for urological applications, particularly in the diagnosis and treatment of prostate cancer. The flagship ExactVu system operates at 29 MHz, providing exceptional imaging resolution that allows for the visualization and targeting of suspicious regions within the prostate. This technology facilitates both targeted and systematic TRUS biopsies, enhancing the accuracy of prostate cancer diagnostics. Additionally, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI data to further improve imaging and biopsy guidance. Founded in 2003 and originally named Imagistx, Inc., the company rebranded to Exact Imaging in March 2015.

KisoJi Biotechnology is an early-stage biotechnology company focused on the development of innovative antibodies for cancer treatment and other therapeutic indications. The company employs a unique approach that allows for the comprehensive identification and visualization of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's antibody platform features multi-species single-domain antibody transgenic mice and utilizes AI-driven antibody fingerprinting to match specific epitopes on various targets. This technology enables the creation of robust, easily manufacturable multi-specific antibodies, aimed at significantly improving treatment outcomes for cancer patients. Through its advanced methodologies, KisoJi is positioned to enhance the efficacy of cancer therapies and contribute to the broader field of oncology.

Endotronix Inc. is a medical technology company based in Lisle, Illinois, founded in 2007. It specializes in the development of advanced hemodynamic monitoring solutions aimed at improving the management of heart failure. The company’s flagship product is a miniaturized, wireless implantable pressure sensor that is designed to be used during interventional cardiovascular procedures. This sensor interfaces with an external measurement device and is part of a broader platform that includes a cloud-based disease management system. Through its innovative technology, Endotronix enables healthcare professionals to detect worsening heart failure earlier, facilitating proactive patient management and enhancing clinical outcomes. The company's approach connects patients, clinicians, and reimbursement teams, providing a comprehensive solution for outpatient hemodynamic management.

Opsens Inc. is a Canadian company that specializes in developing, manufacturing, and selling fiber optic sensors for various applications, primarily in interventional cardiology and industrial markets. It operates in two main segments: Medical and Industrial. The Medical segment focuses on physiological measurements, including Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR), and offers products such as the OptoWire, an advanced optical pressure guidewire, and miniature optical sensors for pressure and temperature measurement. These sensors are designed for integration into medical devices, catering to needs in areas like transcatheter aortic valve replacement. The Industrial segment provides fiber optic sensing solutions for diverse applications, including life sciences, energy, and civil engineering. Opsens markets its products through a direct sales force and distributors across the United States, Japan, Canada, and internationally, with its headquarters located in Québec, Canada.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

This national mobile wellness rewards initiative harnesses the public’s affinity for popular loyalty points, the convenience of smart phone technology and Canadians’ natural desire to lead healthier lives. It is this unique combination that results in such a powerful “nudge” platform – in support of a healthier

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

First Aid Shot Therapy, founded in 2010 and headquartered in Burlingame, California, specializes in clinical beverages aimed at addressing acute and chronic health needs. The company offers a variety of easy-to-swallow, single-dose products that provide rapid relief for common everyday symptoms such as hangover, pain, sleep issues, cold, allergy, and heartburn. By focusing on fast-acting solutions, First Aid Shot Therapy aims to help consumers manage their symptoms quickly and conveniently.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, particularly targeting diabetic nephropathy. Founded in 2005 and headquartered in Research Triangle Park, North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to address complications associated with diabetes. This drug binds to a specific molecular target within the αVβ3 receptor, aiming to mitigate the harmful effects of hyperglycemia and improve patient outcomes. Vascular Pharmaceuticals operates at the intersection of biotechnology and healthcare, committed to innovative solutions for diabetes-related complications.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

OsteoQC Inc is a company that develops new drugs and therapies for the treatment of bone-related diseases.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, founded in 2003. The company specializes in the design and development of non-fusion motion preservation systems for treating degenerative diseases of the cervical and lumbar spine. Its flagship products, the M6-C and M6-L artificial discs, offer innovative options for artificial cervical and lumbar disc replacements, respectively. These discs are uniquely engineered to replicate the anatomical and biomechanical properties of natural intervertebral discs by incorporating an artificial nucleus and annulus. Spinal Kinetics collaborates with spine surgeons to enhance the effectiveness of its devices, which are distributed in various countries, including Australia, Germany, Spain, and the United Kingdom. The company operates as a subsidiary of Orthofix Medical Inc.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company headquartered in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's efforts are concentrated on targeted patient populations in the United States and China, where it seeks to provide innovative solutions for conditions that currently lack effective treatments.

Aptose Biosciences Inc. is a clinical-stage biotechnology company based in Toronto, Canada, that focuses on the discovery and development of personalized therapies for oncology. The company is dedicated to addressing unmet medical needs in cancer treatment and has a pipeline that includes novel small molecule therapeutics aimed at enhancing efficacy while minimizing overlapping toxicities. Its lead clinical program, APTO-253, is currently in a Phase 1b trial for patients with relapsed or refractory blood cancers, such as acute myeloid leukemia and high-risk myelodysplastic syndrome. Aptose is also collaborating with CrystalGenomics on CG026806, a small molecule in Phase 1a/b trials targeting similar malignancies, and has partnered with OHM Oncology for the development of APL-581, which is intended for hematologic cancers. Founded in 1986 and formerly known as Lorus Therapeutics Inc., Aptose Biosciences continues to advance its innovative approach to cancer treatment through both its internal research and strategic partnerships.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, that specialized in the development of individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 1997 and formerly known as Merix Bioscience, the company utilized its proprietary Arcelis technology platform to create personalized treatments. Its notable product candidates included rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, aimed at treating human immunodeficiency virus in Phase II trials. Other investigational products included treatments for transplant rejection and autoimmune diseases. However, Argos Therapeutics filed for Chapter 7 bankruptcy and ceased operations on September 24, 2019.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company headquartered in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's efforts are concentrated on targeted patient populations in the United States and China, where it seeks to provide innovative solutions for conditions that currently lack effective treatments.

Vendorlink.ca is a provider of web-based vendor management solutions specifically designed for the healthcare sector. The company offers a platform that enables hospitals to enforce their policies while ensuring patient safety and privacy through effective vendor training and monitoring. Its comprehensive tools facilitate the management of vendor credentials, activities, and behaviors, allowing healthcare facilities to maintain high standards. Additionally, Vendorlink.ca employs a dedicated team to verify each vendor's credentials before they are published on the vendor's profile, ensuring accuracy and reliability. For vendors, the platform functions as a third-party credentialing system, granting hospitals instant access to essential credentials at all times.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.